Testosterone enantate benzilic acid hydrazone Chemical compound
Pharmaceutical compound
Testosterone enantate benzilic acid hydrazone Trade names Climacteron, Lactimex, Lactostat Other names Testosterone enantate benziloylhydrazone; Testosterone 17β-enantate 3-benzilic acid hydrazone; TEBH; TEBAH; TEBaH Routes of administration Intramuscular injection [ 1] [ 2]
[(3Z ,8R ,9S ,10R ,13S ,14S )-3-[(2-Hydroxy-2,2-diphenylacetyl)hydrazinylidene]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a ]phenanthren-17-yl] heptanoate
CAS Number PubChem CID DrugBank ChemSpider UNII Formula C 40 H 52 N 2 O 4 Molar mass 624.866 g·mol−1 3D model (JSmol )
CCCCCCC(=O)OC1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C/C(=N\NC(=O)C(C5=CC=CC=C5)(C6=CC=CC=C6)O)/CC[C@]34C)C
InChI=1S/C40H52N2O4/c1-4-5-6-13-18-36(43)46-35-22-21-33-32-20-19-30-27-31(23-25-38(30,2)34(32)24-26-39(33,35)3)41-42-37(44)40(45,28-14-9-7-10-15-28)29-16-11-8-12-17-29/h7-12,14-17,27,32-35,45H,4-6,13,18-26H2,1-3H3,(H,42,44)/b41-31-/t32-,33-,34-,35?,38-,39-/m0/s1
Key:PTVXYACXDYZNID-JKNBFTAXSA-N
Testosterone enantate benzilic acid hydrazone (TEBH ), or testosterone 17β-enantate 3-benzilic acid hydrazone , is a synthetic , injected androgen /anabolic steroid and an androgen ester – specifically, the C17β enantate (heptanoate ) ester and C3 benzilic acid hydrazone of testosterone .[ 1] [ 2] It was previously marketed in combination with estradiol benzoate and estradiol dienantate under the brand names Climacteron , Lactimex , and Lactostat .[ 2] [ 3] [ 4] Clinical studies have assessed this formulation.[ 5] [ 6] [ 7] [ 8] [ 9] [ 10] [ 11] [ 2] TEBH was first described in the scientific literature in 1959.[ 12] It is a very long-lasting prodrug of testosterone when administered in oil via intramuscular injection .[ 13] [ 14] [ 15]
Chemistry
Chemical synthesis of TEBH has been described.[ 16]
See also
References
^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer. pp. 641–. ISBN 978-1-4757-2085-3 .
^ a b c d Al-Imari L, Wolfman WL (September 2012). "The safety of testosterone therapy in women". J Obstet Gynaecol Can . 34 (9): 859– 865. doi :10.1016/S1701-2163(16)35385-3 . PMID 22971455 .
^ Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis . Georg Thieme Verlag. 1969.
^ Zentralblatt für Gynäkologie . J. A. Barth. 1971.
^ Sherwin BB, Gelfand MM (March 1984). "Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause". Am. J. Obstet. Gynecol . 148 (5): 552– 7. doi :10.1016/0002-9378(84)90746-4 . PMID 6367474 .
^ Sherwin BB, Gelfand MM (January 1985). "Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause". Am. J. Obstet. Gynecol . 151 (2): 153– 60. doi :10.1016/0002-9378(85)90001-8 . PMID 3881960 .
^ Sherwin BB (September 1985). "Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal women". Maturitas . 7 (3): 225– 33. doi :10.1016/0378-5122(85)90044-1 . PMID 4079822 .
^ Sherwin BB, Gelfand MM (1985). "Sex steroids and affect in the surgical menopause: a double-blind, cross-over study". Psychoneuroendocrinology . 10 (3): 325– 35. doi :10.1016/0306-4530(85)90009-5 . PMID 3903822 . S2CID 40861936 .
^ Sherwin BB, Gelfand MM, Schucher R, Gabor J (February 1987). "Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations". Am. J. Obstet. Gynecol . 156 (2): 414– 9. doi :10.1016/0002-9378(87)90295-X . PMID 3826177 .
^ Sherwin BB (1988). "Affective changes with estrogen and androgen replacement therapy in surgically menopausal women". J Affect Disord . 14 (2): 177– 87. doi :10.1016/0165-0327(88)90061-4 . PMID 2966832 .
^ Sherwin BB (1988). "Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women". Psychoneuroendocrinology . 13 (4): 345– 57. doi :10.1016/0306-4530(88)90060-1 . PMID 3067252 . S2CID 24695692 .
^ Gleason CH, Parker JM (September 1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17 alpha-hydroxy-progesterone-17-heptanoate". Endocrinology . 65 (3): 508– 11. doi :10.1210/endo-65-3-508 . PMID 13828402 .
^ Dodek SM (December 1960). "The hormonal control of lactation". Clin Obstet Gynecol . 3 (4): 1099– 108. doi :10.1097/00003081-196003040-00022 . PMID 13723335 .
^ Greenblatt RB, Barfield WE, Jungck EC (January 1962). "The treatment of the menopause" . Can Med Assoc J . 86 (3): 113– 4. PMC 1848811 . PMID 13901504 .
^ Kelly MJ, Primrose T (December 1960). "Evaluation of a new preparation for the suppression of lactation" . Can Med Assoc J . 83 (24): 1240– 2. PMC 1938994 . PMID 13752392 .
^ Gleason CH (July 1964). "Testosterone 17-Heptanoate 3-Benziloylhydrazone". J. Med. Chem . 7 (4): 573. doi :10.1021/jm00334a042 . PMID 14221154 .
Androgens (incl. AAS Tooltip anabolic–androgenic steroid )
Antiandrogens
AR Tooltip Androgen receptor antagonists Steroidogenesis inhibitors
Antigonadotropins
D2 receptor antagonists (prolactin releasers ) (e.g., domperidone , metoclopramide , risperidone , haloperidol , chlorpromazine , sulpiride )
Estrogens (e.g., bifluranol , diethylstilbestrol , estradiol , estradiol esters , ethinylestradiol , ethinylestradiol sulfonate , paroxypropione )
GnRH agonists (e.g., leuprorelin )
GnRH antagonists (e.g., cetrorelix )
Progestogens (incl., chlormadinone acetate , cyproterone acetate , hydroxyprogesterone caproate , gestonorone caproate , medroxyprogesterone acetate , megestrol acetate )
Others
AR Tooltip Androgen receptor
Agonists SARMs Tooltip Selective androgen receptor modulator Antagonists
GPRC6A